# Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

> **NCT06924606** · PHASE2 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Advanced NSCLC

## Interventions

- **DRUG:** JS207 injection +docetaxel
- **DRUG:** JS207 injection +JS004 injection
- **DRUG:** JS207 injection

## Key facts

- **NCT ID:** NCT06924606
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2026-06-26
- **Final completion:** 2026-06-26
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06924606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06924606, "Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT06924606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*